NCT05976945Active, not recruiting

Imagery Rescripting as Treatment for Depression

Imagery Rescripting as a Stand-alone Treatment for Depression: a Pilot Study.

Source: ClinicalTrials.gov · Last updated 6 May 2026

Brief summary (registry, in English)

The goal of this multiple baseline case series study is to test Imagery Rescripting in depression. The main question\[s\] it aims to answer are: * does Imagery Rescripting lead to a reduction of depression and of believability of negative beliefs held by the participants? * does Imagery Rescripting also leads to reductions in worrying and brooding? * Participants will wait for 6-10 weeks (to assess time effects without treatment), followed by 5 weekly preparation sessions, 8-12 weekly Imagery Rescripting sessions, and 5 weeks post-treatment. * Participants will rate the believability of 3-5 core dysfunctional beliefs related to their depression as well as 2 items assessing depression severity on a weekly basis. In addition, they will fill out more extensive questionnaires on depression, worry and brooding before each phase, as well as at 5 weeks post-treatment, and 6 and 12 months follow-up.

Status (registry): Active, not recruiting
Study type: Interventional
Enrollment: 10 (estimated)
First submitted: 27 Jul 2023
Start date: 10 Aug 2023
Primary completion date: 1 Aug 2026
Lead sponsor: University of Amsterdam
Diseases: Depression
NCT number: NCT05976945

What you commit to

Study type: Interventional
Planned participants: 10
From 10 Aug 2023 to the primary completion date, 1 Aug 2026
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Start of new medication within 2 months before beginning the study (medication used for longer periods can be continued; patients are requested to keep medication stable during the course of the study)
Having received ImRs (either as a stand-alone or embedded in a greater treatment such as cognitive behavior therapy (CBT) or schema therapy) within the last year
Not able to plan enough time for weekly therapy sessions (45-60 minutes); weekly measurements (estimate of 5 minutes) and other measurements (estimate of 20 minutes); and the qualitative post-treatment interview (estimate of 60 minutes) during the study period.

Other illness

DSM-5 Bipolar disorder, type 1 (current or past); if there has been no manic episode the last year patients will be included
Psychotic disorders (though psychotic features alongside depression will be allowed)
Organic brain disease

Other

Intelligence Quotient (IQ) \< 80
High risk of self-harm or suicide
Current substance abuse severe level
No other evidence-based treatment of MDD is allowed during the study.

Who the study is looking for

Primary diagnosis of MDD as assessed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (SCID-5)
Total score of 20\* or above on the BDI-II (cut-off score for moderate depression) (Beck et al., 1996). (\*Based on previous research by Brewin et al. (2009) \& Yuen-tin (2017) demonstrating averages of BDI-II: 34-35, in their population.)
Age 18-65
Dutch or English as a first language (or estimated as sufficient to receive treatment in either of these languages without interpreter)
Willingness to participate in the study (signed informed consent)

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Academic Center for Trauma and Personality ACTP Coordinator of this site? Confirm its status	Amsterdam	Netherlands	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.